2017 Oncology Highlights
Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com
“2017 Oncology Development Review” from Bruno Pagliari
Bruno Pagliara, principal of On-Kos Pharma Consulting in Milan, Italy, publishes regularly reviews on the status of worldwide oncology clinical portfolio. You will find herewith some of the highlights of his most recent report published in the January 2018 issue of MedNous. www.mednous.com
Approvals and line extensions
Oncology drug approvals accelerated in 2017, with a total of 18 new drugs approved during the year in either the EU, the US or Japan. The previous record was 14 new drugs in 2012. Novartis launched three of them. In addition, already marketed drugs received 37 new indications, in some cases, multiple indications for the same drug.
New mechanisms of action
Among the 18 new drugs approved, five have entirely new mechanism of action.
Two new “first in class” chimeric antigen receptor (CAR) T cell therapies, have been approved by the US FDA within a few weeks difference. Novartis’ Kymriah or tisagenlecleucel, for a 3rd line treatment of acute lymphoblastic leukemia, and Gilead’s (former Kite Pharma) KTEC19 for a 3rd line treatment of diffuse large B cell lymphoma.
Lutathera, a lutenium octreotide, a nuclear medicine from Advanced Accelerator Applications (AAA), another first of a kind, was approved in the US, for the treatment of gastroenteropancreatic neuroendocrine tumors. Shortly after the approval AAA, a France based company, was acquired by Novartis.
Immuno-oncology
The new immuno-oncology sector further expanded last year. Fifteen out of the 55 new drugs and new indications were checkpoint inhibitors. One of the success factor of this class of compounds is linked to its rapid onset and long-lasting effect. However, only a small minority of patients receiving the drug respond positively.
Regulatory
Amongst other novelties, it is worthwhile noting the rise, both in the EU and in the US, of oncology drug approvals based on single-arm studies.
The US FDA continues of being the regulator of choice for oncology submissions. In 2017, 14 out of the 18 new drugs received their first market authorization in the US and 28 of the 37 new indications were delivered by the US regulator.
32 drugs have received US FDA “breakthrough therapy designation” or European Priority Medicine (PRIME) status
Looking into 2018
According to Pagliara’s study, eight oncology drugs and 17 new indications, for already approved drugs, are currently under regulatory review. On 31 December 2017, the global oncology pipeline has reached a record high with eight new drugs in pre-registration, 133 in Phase 3 or registration trials, 267 in Phase 2 and 766 in Phase 1.
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.
Last News
- Note de réflexion de fin d’année
- EMA re-examines its opinion and approves Leqembi for the treatment of Alzheimer’s disease
- Le déclassement de la France
Events
News archives
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012